Published 10 days ago • United States • Updated 10 days ago

Press Release: Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis

Summary by Benzinga

Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis If approved, tolebrutinib would be the first and only brain-penetrant BTK inhibitor to both treat non-relapsing secondary progressive multiple sclerosis (MS) and slow disability accumulation independent of relapse activity Tolebrutinib has the potential to be the first therapy to target smoldering neuroinflammation, a key driver of dis…

6 Articles

All

Left

Center

Right

Benzinga

Center

Press Release: Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis

10 days ago·New York, United States

Read Full Article

mja.com.au

Consensus recommendations on multiple sclerosis management in Australia and New Zealand: part 2

A safe, effective and comprehensive approach to managing MS is crucial for improving long term outcomes and quality of life in individuals affected by MS

10 days ago

Read Full Article

neurologylive.com

FDA Accepts Regulatory Submission for BTK Inhibitor Tolebrutinib for Non-Relapsing Secondary Progressive MS

Tolebrutinib's potential approval as the first brain-penetrant BTK inhibitor for non-relapsing secondary progressive MS could represent a paradigm shift in treating disability driven by smoldering neuroinflammation.

10 days ago

Read Full Article

Anti-Aging, Acupuncture and Health News

Neurology Patient Frailty: A Clinician's Guide

Frailty — a clinical syndrome characterized by decreased physiological reserve and increased vulnerability to stressors — has traditionally been associated with geriatric medicine but has profound implications for neurology. Increasing evidence indicates that frailty affects the risk, clinical presentation, and course of common neurologic disorders, including dementia, Parkinson’s disease (PD), stroke, and multiple sclerosis (MS) […] The post Ne…

10 days ago

Read Full Article

Pharmaphorum

FDA starts review of Sanofi's MS hope tolebrutinib

Sanofi's oral BTK inhibitor tolebrutinib is heading towards an FDA decision in September as a potential treatment for multiple sclerosis

10 days ago

Read Full Article

Medscape

Frailty in the Neurology Patient: What Clinicians Need to Know

Frailty is a complex syndrome that may be under-recognized yet can complicate the clinical trajectory of neurologic diseases like dementia, Parkinson’s, multiple sclerosis, and stroke. Medscape Medical News

10 days ago·United States

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Coverage Details

Total News Sources6

Leaning Left0Leaning Right0Center1Last Updated9 days agoBias Distribution

100% Center

Bias Distribution

100% of the sources are Center

100% Center

Untracked bias

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Medscape broke the news in United States 10 days ago on Tuesday, March 25, 2025.

Sources are mostly out of United States (2)

Press Release: Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis

6 Articles

6 Articles

Press Release: Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis

Consensus recommendations on multiple sclerosis management in Australia and New Zealand: part 2

FDA Accepts Regulatory Submission for BTK Inhibitor Tolebrutinib for Non-Relapsing Secondary Progressive MS

Neurology Patient Frailty: A Clinician's Guide

FDA starts review of Sanofi's MS hope tolebrutinib

Frailty in the Neurology Patient: What Clinicians Need to Know

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics